| Active substance | efgartigimod alfa |
| Holder | Argenx |
| Status | closed |
| Indication | add-on to standard therapy treatment for patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and who demonstrate inadequate response to conventional treatments, are not clinically eligible or with contra-indication to treatment with approved and commercially available treatment and are not eligible to participate in a clinical trial |
| Public documents | Approbation |
| Approbation amendment | |
| Information for the patient | |
| Informed consent | |
| Last update |
07/02/2024 |
Vyvgart
Last updated on 13/09/2024